NextCure Inc
NXTC5.140USD
+0.250+5.11%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
143.95MCap. mercado
PérdidaP/E TTM
Más Datos de NextCure Inc Compañía
NextCure, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on advancing medicines that treat cancer patients that do not respond to, or have disease progression on, current therapies, through the use of differentiated mechanisms of actions including Antibody-Drug Conjugates (ADCs), antibodies, and proteins. The Company focuses on advancing therapies that leverage its core strengths in understanding biological pathways and biomarkers, the interactions of cells, including in the tumor microenvironment, and the role each interaction plays in a biologic response. Its product candidates include NC410 and LNCB74. Its Clinical Oncology Programs are NC525 and NC318. Its Pre-Clinical Non-Oncology Programs are NC605 and NC181. NC410 is a LAIR-2 fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers. NCB74 is an ADC that is directed to B7-H4, a clinically validated cancer target.
Información de la empresa
Símbolo de cotizaciónNXTC
Nombre de la empresaNextCure Inc
Fecha de salida a bolsaMay 09, 2019
Director ejecutivoMr. Michael Richman
Número de empleados43
Tipo de seguridadOrdinary Share
Fin del año fiscalMay 09
Dirección9000 Virginia Manor Rd Ste 200
CiudadBELTSVILLE
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal20705-4214
Teléfono12403994900
Sitio Webhttps://www.nextcure.com/
Símbolo de cotizaciónNXTC
Fecha de salida a bolsaMay 09, 2019
Director ejecutivoMr. Michael Richman
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Michael Richman
Mr. Michael Richman
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
34.69K
+2.46%
Dr. David S. Kabakoff, Ph.D.
Dr. David S. Kabakoff, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
5.19K
--
Dr. Udayan Guha, M.D., J.D.
Dr. Udayan Guha, M.D., J.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. John G. Houston, Ph.D.
Dr. John G. Houston, Ph.D.
Independent Director
Independent Director
--
--
Dr. Anne Borgman, M.D.
Dr. Anne Borgman, M.D.
Independent Director
Independent Director
--
--
Dr. Elaine V. Jones, Ph.D.
Dr. Elaine V. Jones, Ph.D.
Independent Director
Independent Director
--
--
Mr. Kevin G. Shaw, J.D.
Mr. Kevin G. Shaw, J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
--
--
Dr. Timothy Mayer, Ph.D.
Dr. Timothy Mayer, Ph.D.
Chief Operating Officer
Chief Operating Officer
--
--
Dr. Sol Langermann, Ph.D.
Dr. Sol Langermann, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. Sourav Kundu, Ph.D.
Dr. Sourav Kundu, Ph.D.
Senior Vice President - Development and Manufacturing
Senior Vice President - Development and Manufacturing
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Michael Richman
Mr. Michael Richman
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
34.69K
+2.46%
Dr. David S. Kabakoff, Ph.D.
Dr. David S. Kabakoff, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
5.19K
--
Dr. Udayan Guha, M.D., J.D.
Dr. Udayan Guha, M.D., J.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. John G. Houston, Ph.D.
Dr. John G. Houston, Ph.D.
Independent Director
Independent Director
--
--
Dr. Anne Borgman, M.D.
Dr. Anne Borgman, M.D.
Independent Director
Independent Director
--
--
Dr. Elaine V. Jones, Ph.D.
Dr. Elaine V. Jones, Ph.D.
Independent Director
Independent Director
--
--
Desglose de ingresos
FY2021
FY2020
Sin datos
Por regiónUSD
Nombre
Ganancia
Proporción
United States
0.00
0.00%
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: vie., 1 de ago
Actualizado: vie., 1 de ago
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Sofinnova Investments, Inc
8.32%
Affinity Asset Advisors LLC
7.17%
Pfizer Inc
6.14%
Citi Investment Research (US)
4.42%
OrbiMed Advisors, LLC
3.55%
Other
70.40%
Accionistas
Accionistas
Proporción
Sofinnova Investments, Inc
8.32%
Affinity Asset Advisors LLC
7.17%
Pfizer Inc
6.14%
Citi Investment Research (US)
4.42%
OrbiMed Advisors, LLC
3.55%
Other
70.40%
Tipos de accionistas
Accionistas
Proporción
Hedge Fund
11.47%
Investment Advisor/Hedge Fund
9.20%
Venture Capital
8.38%
Corporation
6.14%
Investment Advisor
5.03%
Research Firm
4.42%
Private Equity
3.55%
Individual Investor
1.65%
Family Office
0.12%
Other
50.03%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
90
1.31M
49.02%
-419.80K
2025Q1
93
15.91M
56.72%
-4.70M
2024Q4
99
16.68M
59.57%
-2.91M
2024Q3
113
18.48M
66.07%
-4.88M
2024Q2
115
18.65M
66.68%
-4.54M
2024Q1
124
18.78M
67.32%
-1.96M
2023Q4
131
15.99M
57.34%
-5.33M
2023Q3
145
15.65M
56.21%
-6.81M
2023Q2
152
15.96M
57.33%
-6.41M
2023Q1
194
15.85M
57.06%
-8.98M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Sofinnova Investments, Inc
2.67M
9.53%
--
--
Mar 31, 2025
Affinity Asset Advisors LLC
2.30M
8.21%
--
--
Mar 31, 2025
Pfizer Inc
1.97M
7.03%
+79.00K
+4.18%
Apr 23, 2025
Citi Investment Research (US)
1.42M
5.06%
+30.33K
+2.18%
Mar 31, 2025
OrbiMed Advisors, LLC
1.14M
4.07%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
987.32K
3.52%
--
--
Mar 31, 2025
Cable Car Capital LLC
670.10K
2.39%
+54.22K
+8.80%
Mar 31, 2025
Acadian Asset Management LLC
488.44K
1.74%
--
--
Mar 31, 2025
Renaissance Technologies LLC
479.96K
1.71%
-39.34K
-7.58%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
465.54K
1.66%
-1.10K
-0.24%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
iShares Micro-Cap ETF
0%
Avantis US Small Cap Equity ETF
0%
iShares Micro-Cap ETF
Proporción0%
Avantis US Small Cap Equity ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
